Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease

Journal of Hepatology

Volumn 38, Issue 1, 2003, Pages 32-38

  Sumida, Yoshio ^a   Nakashima, Toshiaki ^a   Yoh, Takaharu ^a   Furutani, Masanori ^a   Hirohama, Akihisa ^a   Kakisaka, Yuko ^a   Nakajima, Yoshiki ^a   Ishikawa, Hiroki ^a   Mitsuyoshi, Hironori ^a   Okanoue, Takeshi ^a   Kashima, Kei ^a   Nakamura, Hajime ^b   Yodoi, Junji ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Ferritin; Iron; Nonalcoholic steatohepatitis; Oxidative stress; Thioredoxin

Indexed keywords

FERRITIN; IRON; THIOREDOXIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER LEVEL; MALE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PARAMETER; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; STEATOHEPATITIS;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; FERRITINS; HEPATITIS; HUMANS; IRON; LIVER; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; ROC CURVE; SEVERITY OF ILLNESS INDEX; THIOREDOXIN;

EID: 0037232972     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00331-8     Document Type: Article

References (42)

1. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
2. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
3. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109.
4. Day CP, James OFW. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998;29:1463-1466.
5. Sheth SG, Gordon FD, Chopra S. Non alcoholic steatohepatitis. Ann Intern Med 1997;126:137-145.
6. Ludwig J, McGill DB, Lindor KD. Nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997;12:398-403.
7. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
8. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 1997;94:3633-3638.
9. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol 1997;15:351-369.
10. Holmgren A. Thioredoxin. Annu Rev Biochem 1985;54:237-271.
11. Nakamura H, De Rosa SC, Yodoi J, Holmgren A, Ghezzi P, Herzenberg LA, et al. Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc Natl Acad Sci USA 2001;27:2688-2693.
12. Yoshida S, Katoh T, Tetsuka T, Uno K, Matsui N, Okamoto T. Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF-α-induced production of IL-6 and IL-8 from cultured synovial fibroblasts. J Immunol 1999;163:351-358.
13. Nakamura H, Bai J, Nishinaka Y, Ueda S, Sasada T, Ohshio G, et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prevent 2000;24:53-60.
14. Sumida Y, Nakashima T, Yoh T, Nakajima Y, Ishikawa H, Mitsuyoshi H, et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 2000;33:616-622.
15. Sumida Y, Nakashima T, Yoh T, Kakisaka Y, Nakajima Y, Ishikawa H, et al. Serum thioredoxin elucidates the significance of serum ferritin as a marker of oxidative stress in chronic liver diseases. Liver 2001;21:295-299.
16. Nakashima T, Sumida Y, Yoh T, Kakisaka Y, Nakajima Y, Ishikawa H, et al. Thioredoxin levels in the sera of untreated hepatitis patients and those treated with glycyrrhizin or ursodeoxycholic acid. Antiox Redox Signal 2000;2:687-694.
17. Cotrim HP, Andrade ZA, Parana R, Portugal M, Lyra LG, Freitans LAR. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 1999;19:299-304.
18. Japanese Society for the Study of Obesity. New criteria of obesity (in Japanese). J Jpn Soc Study Obes 2000;6:18-28.
19. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-1197.
20. Kogaki H, Fujiwara Y, Yoshiki A, Kitajima S, Tanimoto T, Mitsui A, et al. Sensitive enzyme-linked immunosorbent assay for adult T-cell leukemia-derived factor and normal value measurement. J Clin Lab Anal 1996;10:257-261.
21. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurement of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-2113.
22. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
23. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577.
24. Oliver FWJ, Christopher PD. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998;29:495-501.
25. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
26. Day CP, James OFW. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-845.
27. Friedman S. The cellular basis of hepatic fibrosis. N Engl J Med 1993;328:1828-1835.
28. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGFα and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995;96:2461-2468.
29. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with non-alcoholic steatohepatitis. Hepatology 1998;27:128-133.
30. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999;353:1634-1636.
31. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999;30:847-850.
32. Berson A, De Beco V, Letterson P, Robin MA, Moreau C, El Kahwaji J, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998;114:764-774.
33. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999;31:421-429.
34. George DK, Goldwurm S, Macdonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318.
35. Sohda T, Yanai J, Soejima H, Tamura K. Frequencies in the Japanese population of HFE gene mutations. Biochem Genet 1999;37:63-68.
36. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999;117:1155-1163.
37. Davis RJ, Corvera S, Czech MP. Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 1986;261:8708-8711.
38. Pietrangelo A. Metals, oxidative stress and hepatic fibrogenesis. Semin Liver Dis 1996;16:13-30.
39. Washington K, Wright K, Shyr Y, Hunter EB, Olson S, Raiford DS. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol 2000;31:822-828.
40. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362.
41. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, et al. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-κB. J Biol Chem 1999;274:27891-27897.
42. Nakashima T, Sumida Y, Yoh T, Kakisaka Y, Mitsuyoshi H, Okanoue T, et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with nonalcoholic steatohepatitis. Gastroenterology 2001;120(Suppl 1):A107.